Abbott has announced the launch of its NeuroSphere myPath digital health app, designed to track and report patient perceived pain relief and general well-being associated with spinal cord stimulation (SCS) or dorsal root ganglion (DRG) therapy. These reports are then sent to the physicians prior to device implantation.
According to a company press release, before committing to full implantation of a neuromodulation device, patients undergo a trial period to test device capabilities and capacity for pain relief. During the trial, temporary leads are placed and connected to an external generator, allowing patients to experience first-hand the impact of neuromodulation on their chronic pain and related symptoms.
“The current digital healthcare landscape has revolutionised our ability to provide direct care for patients whenever they need,” commented Shachi Patel (Delmarva Pain and Spine Center, Newark, USA). “By providing patients with a more seamless, easier way to record their progress during the trial period, Abbott’s NeuroSphere myPath app will enable an enhanced communication experience while providing patients with further insight on their overall outcomes and response to neuromodulation.”
The company reports the neuroSphere myPath will be compatible with Abbott’s Proclaim XR SCS System for patients living with chronic pain in the trunk and limbs, and Proclaim DRG Neurostimulation System for patients with chronic pain in the lower limbs caused by complex regional pain syndrome or causalgia.
“As clinicians, we are constantly in search of more intuitive tools and easy-to-use applications that enable us to provide better care for our patients living with chronic pain – particularly when trialing a new treatment,” said Pankaj Mehta (Pain Specialists in Austin, Austin, USA). “Assessing a patient’s response to a new stimulation therapy is essential to determining a therapeutic course-of-action. With Abbott’s NeuroSphere myPath app, I will have the ability to assess the information patients have been recording and provide a comprehensive assessment on how they are responding to the therapy.”
The company reports the NeuroSphere myPath will be available on the Apple App Store in the coming weeks and is expected to be available on Android devices in the second quarter of 2021.
